Compare Incyte Corporation (INCY) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Palo Alto Networks Inc — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Palo Alto Networks Inc trades at $341.16 (market cap $284.16B). The key difference: Palo Alto Networks Inc is far larger — about 12.3× Incyte Corporation's market cap. Which is the better fit depends on your goals.
| INCY | PANW | |
|---|---|---|
Market Cap | $23.11B | $284.16B |
Sector | Health | Technology |
52-Week High | $118.52 | $358.68 |
52-Week Low | $67.38 | $141.67 |
Enterprise Value | $19.13B | $283.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Palo Alto Networks (PANW) trades at $342.15, down 4.61% today, yet maintains a bullish technical trend with strong analyst support. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.85 surpassing the $0.793 estimate. The company shows robust revenue growth, reaching $9.22B in 2025, and positive cash flow trends, though valuation ratios like a P/E of 303.18 remain elevated. News highlights focus on AI-driven cybersecurity demand and strategic acquisitions, such as the intent to enhance its observability platform announced on July 21, 2026.
Outlook is positive due to strong market positioning in cybersecurity and AI integration, but high valuations and competitive pressures pose risks. Investment opportunity lies in sustained earnings growth and sector tailwinds, while investors should monitor execution on guidance and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
